ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
41.87
+0.24 (+0.56%)
As of 12:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close41.63
Open41.29
Bid41.71 x 1000
Ask41.80 x 800
Day's Range41.27 - 42.51
52 Week Range33.43 - 56.50
Volume85,894
Avg. Volume580,457
Market Cap1.848B
Beta (3Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-3.32
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.91
Trade prices are not sourced from all markets
  • ACCESSWIRE

    IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 11, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • ACCESSWIRE

    INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 9, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • GlobeNewswire

    Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition of Modis Therapeutics, Inc., a privately-held biopharmaceutical company, and added MT1621 to its late-stage development pipeline. MT1621 is a novel investigational deoxynucleoside substrate enhancement therapy for the treatment of Thymidine Kinase 2 deficiency (TK2d), an inherited mitochondrial DNA depletion disorder that predominantly affects children and is often fatal. “We welcome Modis to our growing Zogenix team,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix.

  • ACCESSWIRE

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 7, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • Why Shares of Drugmaker Zogenix Dropped 11.4% in August
    Motley Fool

    Why Shares of Drugmaker Zogenix Dropped 11.4% in August

    Surprisingly, it had nothing to do with the pharma company's earnings report.

  • GlobeNewswire

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wire

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.

  • ACCESSWIRE

    IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 3, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • Thomson Reuters StreetEvents

    Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Zogenix Inc Earnings Call

  • Business Wire

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.

  • Motley Fool

    Why Overstock.com, Zogenix, and Mogu Slumped Today

    One of these stocks continued to see fallout from recent executive moves.

  • Why Zogenix Stock Sank Today
    Motley Fool

    Why Zogenix Stock Sank Today

    The biotech is making an acquisition deal that investors don't appear to approve of.

  • TheStreet.com

    Zogenix Drops After Acquiring Modis Therapeutics

    Shares of drugmaker Zogenix were falling sharply Monday after the company announced it acquired privately held Modis Therapeutics for $250 million. Modis is a drug company focused on developing drugs for rare genetic diseases with high unmet medical need, according to a press release announcing the deal.

  • Benzinga

    Zogenix Will Acquire Modis Therapeutics In $250M Deal

    Zogenix, Inc. (NASDAQ: ZGNX ) will acquire Modis Therapeutics, a privately held biopharmaceutical company focused on developing novel therapies for rare genetic diseases for $250 million. Under the terms ...

  • GlobeNewswire

    Zogenix Announces Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) --  Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel therapies for rare genetic diseases with high unmet medical need. Modis’s lead product candidate, MT1621, an investigational deoxynucleoside substrate enhancement therapy, is in late-stage development for the treatment of Thymidine Kinase 2 deficiency (TK2d), an inherited mitochondrial DNA depletion disorder that predominantly affects children and is often fatal.

  • A Holistic Look At Zogenix, Inc. (NASDAQ:ZGNX)
    Simply Wall St.

    A Holistic Look At Zogenix, Inc. (NASDAQ:ZGNX)

    Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...

  • GuruFocus.com

    Zogenix Inc (ZGNX) EVP, CFO, Treasurer & Sec. Michael P Smith Sold $750,000 of Shares

    EVP, CFO, Treasurer & Sec. of Zogenix Inc (30-Year Financial, Insider Trades) Michael P Smith (insider trades) sold 15,000 shares of ZGNX on 08/09/2019 at an average price of $50 a share. Continue reading...

  • Zogenix Inc (ZGNX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Zogenix Inc (ZGNX) Q2 2019 Earnings Call Transcript

    ZGNX earnings call for the period ending June 30, 2019.

  • Steven Cohen Charges Into Chiasma
    GuruFocus.com

    Steven Cohen Charges Into Chiasma

    Guru invests in clinical-stage biopharmaceutical company Continue reading...

  • GlobeNewswire

    Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6

    EMERYVILLE, Calif., July 30, 2019 -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its.

  • How this East Bay biotech moved from an 'error' to a potential treatment for kids with severe seizures
    American City Business Journals

    How this East Bay biotech moved from an 'error' to a potential treatment for kids with severe seizures

    The company's stock dropped 20 percent in April. Now it has largely recovered and is lining up to ask the FDA to approve its drug for Dravet syndrome.

  • Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company?
    Simply Wall St.

    Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Zogenix, Inc...

  • Here's Why Zogenix Leaped 26.8% in June
    Motley Fool

    Here's Why Zogenix Leaped 26.8% in June

    The company rebounded after remedying an embarrassing regulatory gaffe.

  • GlobeNewswire

    Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3 clinical trial of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), a severe and often treatment-resistant childhood-onset epilepsy. Study 1601 is a multi-national, randomized, double-blind, placebo-controlled trial of two fixed doses of FINTEPLA as adjunctive therapy for seizures in children and adults with LGS.  After establishing a baseline seizure frequency for four weeks, patients are randomized into one of three treatment groups (0.2 or 0.8 mg/kg/day FINTEPLA, maximum of 30 mg/day, or placebo) for a two-week period of dose titration before being held at a fixed dose for 12 weeks of maintenance treatment.  The study randomized a total of 263 patients, with approximately 87 subjects per group.  The primary endpoint of the clinical trial is the change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.8 mg/kg/day dose compared to placebo.  The key secondary endpoints include change in the number of drop seizures between baseline and the combined titration and maintenance periods at the 0.2 mg/kg/day dose compared to placebo, and the proportion of patients achieving a 50% reduction in drop seizures.  Patients who complete the maintenance treatment period may be eligible to enter a 12-month open-label extension to evaluate the long-term safety, tolerability and effectiveness of FINTEPLA in LGS.

  • 3 Hot Biotechs Trending Now
    TipRanks

    3 Hot Biotechs Trending Now

    Biotech is a tough market to follow. Promising research avenues hit roadblocks, clinical trials can fail, and regulators can withhold approval. And all of that can happen to companies that frequently operate at a loss, with high initial overhead costs and a long road toward profitability.The rewards, however, are great. A new drug hitting the market, or news of a successful long-term trial, can bring in new investors and give a tremendous boost to a company’s shares. We’ve sorted through the data to find three biotechs that are making waves. These are mid- to large-cap firms, with new drugs in the pipeline or recently released, and high expectations for near-term returns. Amarin Corporation, Plc. (AMRN)Cardiac disease is a leading killer, and the American consumer is willing to pay a premium for cholesterol-reducing drugs of proven efficacy. Amarin has entered that niche with its sole product, Vascepa, a new drug based on Omega-3 fatty acids.You’ve heard of Omega-3, of course – it has been promoted for years as a dietary supplement for cardiovascular health. With Vascepa, Amarin has concentrated the active factors to create, not a supplement, but a hypertriglyceridemia drug for the specific treatment of high cholesterol. Vascepa was approved by the FDA in 2012, was promptly entered into the multi-year REDUCE-IT study, and in September 2018 Amarin announced the study results. In the controlled study of 8000 patients over six years, Vascepa showed significant results in preventing heart attacks. AMRN shares jumped from under $3 per share to over $15, and have held those gains.Now the company is looking to use its profits for expansion. Per Roth Capital’s Yasmeen Rahimi, “Amarin provided record revenue for the first half of 2019 for Vascepa, guided $380M-420M for 2019 and unveiled its plans to increase its U.S. sales team to about 800 in October 2019.” Rahimi sees this move as the beginning for Vascepa, heralding the drug’s conversion to a true money-maker for the Amarin. She gives the stock a $31 price target, suggesting an upside of 33%.Jefferies analyst Michael Yee agrees with the rosy outlook for Vascepa’s profit potential. He notes the “positive pre-announcement with upside Q2 sales beat and full-year guidance raise supporting the thesis of strong Vascepa launch and greater outlook and opportunity than consensus expectations.” Yee adds that he sees the stock moving higher to the upside on increases future sales. His price target, $30, implies a 29% potential for share price gains.Amarin has been doing well, on Vascepa’s strong reviews and success in the market. The stock has a unanimous analyst consensus of ‘Strong Buy,’ based on 6 buy ratings in the past three months. The average price target, $32, gives a 41% upside to the share price of $23.View AMRN Price Target & Analyst Ratings Detail Gilead Sciences, Inc. (GILD)Gilead is well-established in the pharma sector – it’s a major player on the American medical research scene, and holds a dominant position the HCV and HIV drug research segments. Casual consumers are more likely to encounter Gilead through its popular anti-viral drug Tamiflu, marketed as an OTC preventative and treatment for the flu.In recent development, Gilead has been moving filgotinib, a potential treatment for rheumatoid arthritis, forward in testing. Filgotinib is now if Phase III trials, and the company has announced that it will file a New Drug Application with the FDA – the next step in getting approval before marketing.Writing from RBC Capital, four-star analyst Brian Abrahams notes several factors that are boosting GILD stock. Filgotinib’s regulatory progress is prominent on the list. Abrahams also says that stock’s “valuation looks cheap and at a floor,” and points out the “strong balance sheet and solid dividend yield.”That last is an important point; most biotech firms do not pay any dividend, but Gilead initiated payments in 2015. The yield is now up to 3.68%, and payouts are $2.52 annualized, making it a strong incentive for investors. Abrahams’ price target on GILD, $91, indicates a 32% upside to the stock.Alethia Young, of Cantor Fitzgerald, has been following Gilead for several years, and had previously estimated that filgotinib would launch in the US in 2022 with initial sales up to $93 million. Citing the “positive" U.S. filing update,” she now believes that the timeline has moved up by at least one year and sees a potential approval in late 2020. She raised her price target on the stock to $88 to reflect her optimism.Gilead’s overall rating is a ‘Moderate Buy,’ based 13 buys, 5 holds, and 1 sell assigned during the past three months. The stock’s current share price is $68, and the average price target is $79; this gives GILD shares a 15% upside potential.View GILD Price Target & Analyst Ratings Detail Zogenix, Inc. (ZGNX)Like many smaller biotech research firms, Zogenix does not yet have a drug on the market. Unlike most such firms, however, Zogenix’ main research program is a reuse of a previously approved drug, fenfluramine. This was used in the past as a treatment for obesity; Zogenix has been researching its potential has a seizure treatment for children with the rare disease Dravet Syndrome. The studies have reached Phase III, and have shown some promise.The company’s stock took a hit, however, when the FDA last quarter ‘refused to file’ Zogenix’ application for fenfluramine as a new drug, branded Fintepla, for seizure treatment. ZGNX shares lost more than $10, and the company had to shift focus to bureaucratic streams.ZGNX got a boost last month, when the FDA reversed course. Regulators have said that they will permit the new drug application for Fintepla, and without additional preclinical toxicity data. According to Danielle Brill, pharma sector analyst from Piper Jaffray, this was the “best case scenario for Zogenix.” She says, “Although breakthrough therapy status was rescinded due to the recent approvals of two other drugs for Dravet Syndrome, expect an expedited review [with] approval and launch by Q2 of 2020. [Do] not expect the delay to have any meaningful impact on Fintepla's overall commercial potential.” She gives ZGNX shares a $64 price target, suggesting a 34% upside.Difei Yang, of Mizuho, also sees the FDA’s regulatory reversal as a win for Zogenix. She says, “A priority review is highly likely and the FDA's decision is a positive.” Yang bumped her price target up to $65, indicating confidence in a 36% upside.Zogenix’ upbeat regulatory outlook has given it support in the markets. Shares stand at $47, up $8 since the FDA decision. The average price target is $61, giving the stock a 28% upside potential. And like Amarin, the analysts are unanimous on ZGNX – 9 buy ratings give it a ‘Strong Buy’ consensus rating.View ZGNX Price Target and Analyst Ratings DetailVisit TipRanks’ Trending Stocks tool to see what else is hot in today’s markets.